All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

April 27th 2025

Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Neoadjuvant Mitomycin C Demonstrates Favorable Safety and Potential RFS Benefit in NMIBC

April 27th 2025

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Disitamab Vedotin/BCG Could Provide a New Bladder Sparing Therapy in HER2-Expressing High-Risk NMIBC

April 27th 2025

The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

UGN-102 May Represent Alternative to TURBT in Recurrent Low-Grade Intermediate-Risk NMIBC

April 27th 2025

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer

April 26th 2025

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

Cretostimogene Grenadenorepvec Produces Durable CRs in High-Risk BCG-Unresponsive NMIBC

April 26th 2025

Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.

TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC

April 26th 2025

TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.

UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer

April 26th 2025

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

AI in Cancer Care, Targeted Therapies Among Cancer Conference Talks

April 25th 2025

UCSF experts highlight leadership in innovative cancer research and education.